NCT03274804View on ClinicalTrials.gov

Combined PD-1 and CCR5 Inhibition for the Treatment of Refractory Microsatellite Stable mCRC

PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

April 1, 2018

Primary Completion Date

March 1, 2020

Study Completion Date

March 1, 2020

Conditions
Metastatic Colorectal CancerMSS
Interventions
BIOLOGICAL

Pembrolizumab

Eligible subjects will receive pembrolizumab beginning on Day 1 of each 3-week dosing cycle (d1, qd22)

DRUG

Maraviroc

Maraviroc will be administered perorally on day 1 to 21 of each cycle (d1-21; qd22)

Trial Locations (1)

Unknown

National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg

All Listed Sponsors
collaborator

Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest

OTHER

lead

University Hospital Heidelberg

OTHER

NCT03274804 - Combined PD-1 and CCR5 Inhibition for the Treatment of Refractory Microsatellite Stable mCRC | Biotech Hunter | Biotech Hunter